Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an ...
MedPage Today on MSN

Mavacamten Poised to Expand to Pediatric Obstructive Hypertrophic Cardiomyopathy

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat ...

Americas Gold and Silver Announces New Major Discoveries in Idaho and Mexico and a Strong 2025 Resource & Reserve Update Including a 19% Year over Year Increase in M&I Mineral ...

Consolidated silver M&I Mineral Resources increased by 10% to 115.7 million ounces, grade increased by 30% to 239.8 g/t Inferred Mineral Resources increased by 15% to 133.3 million ounces, grade ...
Limerick Leader

The hidden cost of waiting: Limerick families and the ADHD assessment journey

Introduction: The ADHD Assessment Landscape in Limerick. The narrative of mental health provision in the Mid West of Ireland ...
Goldseiten

Americas Gold and Silver Announces New Major Discoveries in Idaho and Mexico and a Strong 2025 Resource & Reserve Update

Americas Gold and Silver is pleased to announce that its consolidated silver Measured and Indicated Mineral Resources has ...